Tanya L Wilton, BPhEd, MBChB, Dip Obs, Registrar.
Cyclooxygenase-2 inhibitors: Do they have a role in emergency department prescribing?
Article first published online: 2 FEB 2004
Volume 16, Issue 1, pages 65–73, February 2004
How to Cite
Wilton, T. (2004), Cyclooxygenase-2 inhibitors: Do they have a role in emergency department prescribing?. Emergency Medicine, 16: 65–73. doi: 10.1111/j.1742-6723.2004.00540.x
Conflicts of interests: None
- Issue published online: 23 FEB 2009
- Article first published online: 2 FEB 2004
- anti-inflammatory agents;
- cyclooxygenase 2;
- cyclooxygenase inhibitors;
- emergency medicine;
Cyclooxygenase-2 selective inhibitors (COXIB or CSI) have been released with a fanfare as efficacious and safer alternatives to traditional non-steroidal anti-inflammatory drugs. They purport to offer equivalent degrees of analgesia and an improved safety profile. COXIB currently available in Australasia are celecoxib (Celebrex), rofecoxib (Vioxx) and etoricoxib (Arcoxia). This review discusses the pharmacology of these agents and reviews recent literature regarding their effectiveness and safety. It endeavours to answer the question ‘Should we be using COXIB in emergency departments in Australasia’?